BNT162b2 (Comirnaty)

Vaccine Atlas · mRNA · Lipid Nanoparticle

Platform: Modified-nucleoside mRNA / ALC-0315 LNP | Route: Intramuscular | Developer: BioNTech SE & Pfizer Inc.

Modified-nucleoside mRNA encoding the SARS-CoV-2 prefusion-stabilized (2P) spike, delivered in an ALC-0315 lipid nanoparticle. Selected from four parallel BNT162 candidates based on balanced immunogenicity and reactogenicity. First authorized COVID-19 vaccine globally (UK MHRA, December 2, 2020) and first mRNA vaccine to receive full regulatory approval (FDA BLA, August 23, 2021). Phase 3 efficacy 95.0% against symptomatic COVID-19. Rare post-marketing myocarditis/pericarditis signal primarily in young males after dose 2.

Comirnaty tozinameran Pfizer-BioNTech COVID-19 vaccine BNT162b2

Overview

BNT162b2 was co-developed by BioNTech SE (founded by Uğur Şahin and Özlem Türeci, Mainz, Germany — originally a personalized mRNA cancer-vaccine platform company) and Pfizer, who joined as manufacturing and global distribution partner in March 2020. BNT162b2 was selected from four parallel candidates (BNT162-a1, -b1, -b2, -b3) differing in mRNA chemistry (modified-nucleoside vs. unmodified) and antigen (full-length 2P spike vs. RBD-only). The b2 candidate — modified-nucleoside, full-length 2P spike — won on its balanced immunogenicity/reactogenicity profile in Phase 1/2 testing.

It was authorized by the UK MHRA on December 2, 2020 — the first regulatory authorization for any COVID-19 vaccine anywhere — and received FDA Emergency Use Authorization on December 11, 2020. Full FDA Biologics License Approval as Comirnaty followed on August 23, 2021, making it the first mRNA vaccine of any kind to receive full regulatory approval. Phase 3 trial C4591001 enrolled 43,448 participants and demonstrated 95.0% efficacy (95% CI 90.3–97.6%) against symptomatic COVID-19 at ≥7 days post-dose 2.

The platform is architecturally near-identical to mRNA-1273 (Moderna/NIH): both use modified-nucleoside mRNA with N1-methylpseudouridine, the same 2P-stabilized spike antigen, and four-lipid LNP delivery. They differ in dose (30 µg vs. 100 µg), dose interval (21 vs. 28 days), and ionizable lipid (ALC-0315 vs. SM-102). The rare post-marketing myocarditis signal is shared across the mRNA platform class, with BNT162b2 showing a lower absolute rate in young males than mRNA-1273, likely reflecting the lower dose.

Platform & Antigen Design

mRNA-LNP Architecture (ALC-0315 formulation)

  mRNA construct (N1-methylpseudouridine modified; 4,284 nt):
    5' cap1 (m7G) → 5' UTR → SARS-CoV-2 spike (2P) CDS → 3' UTR → polyA tail

  Spike antigen: full-length S with K986P + V987P (2P stabilization)
    ┌─ Locks prefusion conformation (RBD-up, immunogenic)
    └─ Prevents premature transition to post-fusion form

  LNP composition (ALC-0315 / Acuitas):
    ALC-0315 (ionizable lipid, ~50%)  → endosomal disruption → cytoplasmic mRNA release
    ALC-0159 (PEG-lipid, ~1.5%)       → surface coating, aggregation prevention
    DSPC (helper phospholipid, ~10%)  → structural stability
    Cholesterol (~38.5%)               → membrane fluidity

  IM injection → LNP endocytosis by muscle cells + dermal DCs
        │
        ├─ Endosomal acidification → ALC-0315 protonation → membrane disruption
        │    mRNA released into cytoplasm
        │
        ├─ Ribosomes translate spike → spike displayed on cell surface
        │
        ├─ MHC I: intracellular spike peptides → CD8⁺ CTL priming
        │
        └─ Secreted/shed spike → B cells in draining lymph node
             Germinal center → anti-RBD IgG (IgG1/IgG3) + memory B cells
             CD4⁺ Th1 support (mRNA platforms Th1-biased)

Modified nucleoside chemistry: Every uridine replaced with N1-methylpseudouridine (m1Ψ) — evades TLR7/TLR8 and RIG-I innate sensing of "foreign" RNA, dramatically increases protein translation and reduces inflammatory reactogenicity.
2P prefusion stabilization: K986P + V987P substitute prolines lock the spike in its prefusion trimer conformation — preserving the RBD neutralizing epitope landscape and preventing post-fusion conformational collapse after mRNA translation.
ALC-0315 ionizable lipid: Near-neutral at physiological pH (minimizes systemic clearance); protonated in late endosome (pH ~5.5) — disrupts endosomal membrane and releases mRNA into cytoplasm for ribosomal translation.
Transient expression: mRNA is degraded by intracellular RNases within days to ~2 weeks. No DNA integration, no reverse transcription, no replication.
Dose 2 recall: Dose 2 (day 21) triggers a recall response against spike antigen presented by residual memory B and T cells — producing a large antibody boost (geometric mean titer rises ~10-fold vs. day 21) and explaining the greater reactogenicity of dose 2.

Immunogenicity

Humoral Response

Robust anti-spike IgG (predominantly anti-RBD IgG1/IgG3). Geometric mean titers after dose 2 ~10× convalescent serum benchmarks. Seroconversion >99%. Anti-RBD IgG titer is the strongest correlate of protection against symptomatic COVID-19.

CD4⁺ / CD8⁺ T-Cell Response

Th1-biased CD4&sup+ responses (IFN-γ, IL-2); spike-specific CD8&sup+ CTLs via MHC I loading. T-cell responses correlate with protection against severe disease where antibody titers have waned. Cellular immunity more durable than humoral over >12 months.

Innate Activation

LNP components (particularly ionizable lipid ALC-0315 and PEG-lipid) activate innate pathways at the injection site — NLRP3 inflammasome, TLR4 signaling — providing adjuvanting activity without exogenous adjuvant. m1Ψ modification attenuates excessive innate sensing of mRNA itself.

Duration / Durability

Neutralizing antibody titers peak ~1–2 weeks post-dose 2, then wane with a half-life of ~69 days. Anti-RBD IgG titers fall ~5–10-fold by 6 months. T-cell responses decline more slowly. Boosters restore peak titers and broaden cross-variant coverage including Omicron sublineages.

Clinical Efficacy

Trial / Study	Design	n	Primary Endpoint	VE%
C4591001 Phase 1/2 (Walsh 2020)	Phase 1/2 dose-ranging, US adults	195	Safety and immunogenicity; 30 µg selected	Strong IgG + T-cell responses; 30 µg dose confirmed
C4591001 Phase 3 (Polack 2020, NEJM)	Phase 3 RCT, 2:1 vaccine:placebo, US+global	43,448	Symptomatic COVID-19 ≥7 days post-dose 2	95.0% (95% CI 90.3–97.6%)
Israel Real-World (Dagan 2021, NEJM)	National matched cohort, 1.2M vaccinees	~1.2M	Symptomatic COVID-19, hospitalization, death	92% symptomatic; 87% hospitalization; 92% severe disease
FDA BLA Full Approval (2021)	Complete phase 3 follow-up + post-market data	>43,000	Sustained efficacy; safety database reviewed	First mRNA vaccine full approval; efficacy confirmed durable at median 6+ months

Safety Profile

Very Common Injection-site pain, fatigue, headache, chills, myalgia — present in >50–80% of vaccinees; more pronounced after dose 2 than dose 1; onset within 24 hours; generally resolves within 1–2 days. Grade 3 reactions (limiting normal activity) in ~3–4% after dose 2.
Common Low-grade fever — ~15% after dose 2; <3% after dose 1; self-limiting. Redness and swelling at injection site common (>10%).
Rare / Serious Myocarditis / pericarditis — predominantly young adult males within 1–7 days of dose 2. Post-marketing surveillance: estimated ~1–10 per 100,000 doses in highest-risk age band (16–29-year-old males), lower absolute rate than mRNA-1273 at equivalent age (reflecting lower 30 µg dose). Most cases mild and self-limiting (median hospital stay 2–4 days; full recovery typical). Mechanism incompletely understood — proposed: molecular mimicry, dysregulated innate-immune LNP response, individual susceptibility.
Very Rare Anaphylaxis — ~1–2 per million doses; typically within 15–30 min; standard 15-min observation period required; related to PEG component of LNP; manageable with epinephrine.
Not Established No VITT association (unlike adenoviral vector vaccines); no thrombocytopenia-thrombosis syndrome signal; no evidence of genomic integration or infertility effects.

Administration

Parameter	Details
Adult dose / schedule	2 doses of 30 µg (0.3 mL), 21 days apart; IM deltoid
Pediatric doses	Ages 5–11: 10 µg (2 doses, 21d apart); ages 6 months–4 years: 3 µg (3 doses); ages ≥12: adult schedule
Booster	Single 30 µg booster ≥5 months after primary; updated bivalent (BA.4/5, XBB) and monovalent formulations followed for annual updates
Storage	Originally −80°C ultra-cold (6 months); reformulated to −20°C (10 weeks) and 2–8°C (10 weeks after thaw); dilution-required multidose vials
Contraindications	Prior anaphylaxis to BNT162b2 or any component (including PEG-lipid); severe allergy to polyethylene glycol; history of myocarditis/pericarditis after BNT162b2 (discuss benefit-risk)

Connections

Elicits Immune System Elicits B Cell (anti-RBD IgG) Elicits T Helper Cell (Th1) Via Dendritic Cell Same Platform mRNA-1273 Same Antigen AZD1222 Immunizes vs. SARS-CoV-2

References

Polack FP, Thomas SJ, Kitchin N, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-2615. doi:10.1056/NEJMoa2034577 · PMID 33301246
Walsh EE, Frenck RW Jr, Falsey AR, et al. Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates. N Engl J Med. 2020;383(25):2439-2450. doi:10.1056/NEJMoa2027906 · PMID 33053279
Dagan N, Barda N, Kepten E, et al. BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting. N Engl J Med. 2021;384(15):1412-1423. doi:10.1056/NEJMoa2101765 · PMID 33626250
Mevorach D, Anis E, Cedar N, et al. Myocarditis after BNT162b2 mRNA Vaccine against Covid-19 in Israel. N Engl J Med. 2021;385(23):2140-2149. doi:10.1056/NEJMoa2109730 · PMID 34614328